PAR2-Mediated Upregulation of BDNF Contributes to Central Sensitization in Bone Cancer Pain by Yanju Bao et al.
MOLECULAR PAIN
Bao et al. Molecular Pain 2014, 10:28
http://www.molecularpain.com/content/10/1/28RESEARCH Open AccessPAR2-mediated upregulation of BDNF contributes
to central sensitization in bone cancer pain
Yanju Bao1, Wei Hou1, Rui Liu1, Yebo Gao1, Xiangying Kong2, Liping Yang3, Zhan Shi1, Weidong Li1,
Honggang Zheng1, Shulong Jiang4, Conghuang Li1, Yinggang Qin1 and Baojin Hua1*Abstract
Background: Bone cancer pain is currently a major clinical challenge for the management of cancer patients, and
the cellular and molecular mechanisms underlying the spinal sensitization remain unclear. While several studies
demonstrated the critical role of proteinase-activated receptor (PAR2) in the pathogenesis of several types of inflammatory
or neuropathic pain, the involvement of spinal PAR2 and the pertinent signaling in the central sensitization is not
determined yet in the rodent model of bone cancer pain.
Findings: Implantation of tumor cells into the tibias induced significant thermal hyperalgesia and mechanical allodynia,
and enhanced glutamatergic strength in the ipsilateral dorsal horn. Significantly increased brain-derived neurotrophic
factor (BDNF) expression was detected in the dorsal horn, and blockade of spinal BDNF signaling attenuated the
enhancement of glutamatergic strength, thermal hyperalgesia and mechanical allodynia in the rats with bone cancer
pain. Significantly increased spinal PAR2 expression was also observed, and inhibition of PAR2 signaling ameliorated
BDNF upsurge, enhanced glutamatergic strength, and thermal hyperalgesia and mechanical allodynia. Inhibition of
NF-κB pathway, the downstream of PAR2 signaling, also significantly decreased the spinal BDNF expression, glutamatergic
strength of dorsal horn neurons, and thermal hyperalgesia and mechanical allodynia.
Conclusion: The present study demonstrated that activation of PAR2 triggered NF-κB signaling and significantly upregulated
the BDNF function, which critically contributed to the enhancement of glutamatergic transmission in spinal dorsal horn and
thermal and mechanical hypersensitivity in the rats with bone cancer. This indicated that PAR2 - NF-κB signaling might
become a novel target for the treatment of pain in patients with bone cancer.
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Bone cancer painIntroduction
Bone cancer pain is currently a major clinical challenge
for the management of cancer patients, because the spe-
cific cellular and molecular mechanisms underlying bone
cancer pain largely remain obscure [1,2]. While lines of
studies have demonstrated the remarkable sensitization of
peripheral nociceptors in the bone, resulting from the
tumor-induced acidosis and cytokine synthesis, emerging
evidences indicated that the activation of astrocytes [3-5]
and altered glutamatergic synaptogenesis [6,7] existed in
the spinal dorsal horn of the rodent model of bone cancer* Correspondence: huabaojin01@163.com
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unless otherwise stated.pain. Overwhelming evidences strongly suggest that brain-
derived neurotrophic factor (BDNF) serves as one of the
key regulators of synaptic plasticity in brain regions in-
cluding cortex, hippocampus as well as spinal cord [8],
and it is critically involved in the induction and mainten-
ance of central sensitization in varieties types of pain [9].
It was previously reported that the synthesis and release of
BDNF was remarkably upregulated, which contributing to
the central sensitization, in the spinal dorsal horn of the
rodent with inflammatory or neuropathic pain [9,10]. Cur-
rently, the role of BDNF in the induction and maintenance
of enhanced spinal glutamatergic transmission has not
been elucidated in the rodent model of bone cancer pain.
Proteinase-activated receptors (PARs) are a family of
G-protein coupled receptors that are activated by prote-
ases, which liberates a tethered ligand, by cleaving the. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cellular signal pathways [11]. Four subtypes of PARs
exist. While PAR1, PAR3, and PAR4 are preferentially
activated by thrombin, PAR2 is preferentially activated
by trypsin and trypsin-like proteinases [12]. All four
PARs are expressed throughout the peripheral and cen-
tral nerve system. In the spinal dorsal horn, PAR2 recep-
tor is located in the microglia, astrocytes, neurons, and
the terminals of afferent fibers originating from the dor-
sal root ganglions [12]. Previous studies demonstrated
the critical involvement of PAR2 in the pathogenesis of
several types of inflammatory or neuropathic pain [12].
Activation of PAR2 signaling participated in the induc-
tion of sensitization of peripheral nociceptors in the ro-
dent model of bone cancer pain [13]. However, it
remains uncertain whether activation of spinal PAR2 sig-
naling is critically involved in the central sensitization in
the rodent model of bone cancer pain.
Besides triggering the mitogen-activated protein kinases
signaling, including ERK1/2, p38 and JNK activity, the acti-
vation of G-protein couple receptor PAR2 also involves
PLC-mediated hydrolysis of phosphatidylinositol 4,5-bispho-
sphate (PIP2) and induction of the Ca
2+/inositol 1,4,5-tris-
phosphate (IP3)/PKC signaling [11], which may in turn
induce the phosphorylation of IKKα and IKKβ and result in
the activation and nuclear translocation of NF-κB [11]. Ac-
cumulating evidence demonstrated that peripheral inflam-
mation or nerve injury induced remarkable NF-κB activity
in the spinal dorsal horn, which contributing to the thermal
hyperalgesia and mechanical allodynia in the rodent models
of chronic pain [14,15]. It was previously reported that up-
regulated NF-κB activity was required for the developmental
and plasticity-associated synaptogenesis in the central neu-
rons [16]. Meanwhile, upregulation of NF-κB activity also fa-
cilitated the expression of BDNF in the central neurons [17].
Here, the present study aims to elaborate the involvement
of PAR2 - NF-κB signaling in the induction of enhanced
spinal glutamatergic transmission and painful behaviors in
the rats with bone cancer.
Results
BDNF contributes to the enhanced glutamatergic
strength in the rats with bone cancer pain
Implantation of tumor cells into the tibias significantly
decreased the ipsilateral paw withdrawal threshold re-
sponsive to the mechanical stimuli (Figure 1C), which
was remarkably detectable at day 5, and maintained
through at least day 15 (the endpoint of the study) after
the procedure. Meanwhile, no significant change of the
ipsilateral paw withdrawal threshold was observed in the
rats receiving boiled cells. Similarly, the ipsilateral paw
withdrawal latencies responsive to the radiant thermal
stimuli were also significantly shortened in the rats im-
planted with tumor cells, which started at day 5 throughday 15 (Figure 1C). These results indicated the bone
cancer-induced mechanical allodynia and thermal hyper-
algesia in the modeled rats.
To determine the adaptation of glutamatergic trans-
mission in the spinal dorsal horn of the rats with bone
cancer pain, the whole cell-recording was performed in
the ipsilateral laminae II neurons in spinal slices (L4-L5),
and the glutamatergic EPSC was recorded in the pres-
ence of strychnine (2 μM) and bicuculline (10 μM). The
EPSC was completely abolished by the perfusion of
CNQX (10 μM) and APV (10 μM), confirm its gluta-
matergic components. Compared to that in the control
rats, the input (intensity of stimuli) –output (amplitude
of evoked EPSC) response was significantly left shifted
(Figure 1B), indicating a significantly enhanced gluta-
matergic strength in the dorsal horn neurons in the rats
with bone cancer pain.
BDNF, synthesized from central neurons and astro-
cytes, is critically involved in the glutamatergic synapto-
genesis and synaptic plasticity in the brain [8]. Here, we
investigated the expression of BDNF in the dorsal horn,
and its functional significance in the bone cancer-
induced pain. As shown in Figure 1A, the expression of
BDNF was significantly increased in the dorsal horn of
the rats with bone cancer pain. The further electro-
physiological recording studies revealed that intrathecal
delivery of TrkB-Fc chimera (1.5 μg, day 3 to day 15),
which quenching the endogenous BDNF, significantly
ameliorated the increase of glutamatergic strength in the
dorsal horn neurons of the rats with cancer-induced
pain (Figure 1B). Behavioral studies demonstrated that
inhibition of BDNF signaling by TrkB-Fc chimera also
significantly attenuated the mechanical allodynia and
thermal hyperalgesia in these modeled rats (Figure 1C).
Note that blockade of the BDNF signaling failed to re-
markably change basal glutamatergic transmission and
pain behavior in the control rats (Figure 1B and C).
These results suggested the critical involvement of
BDNF signaling in the enhanced glutamatergic transmis-
sion in the dorsal horn neurons of the rats with bone
cancer pain.
PAR2 mediated BDNF upregulation and glutamatergic
sensitization in the rats with bone cancer pain
Considering the important role of PAR2 in neuroinflam-
mation and the pathogenesis of several kinds of pain
[12], we next determine the involvement of spinal PAR2
signaling in the induction of the enhancement of spinal
glutamatergic transmission and pain behavior in the rats
implanted with tumor cells. Firstly, as shown in Figure 2A,
the expression of PAR2 was significantly increased in the
dorsal horn of the rats with bone cancer. This indicated
the potential role of PAR2 in the pathogenesis of bone
cancer-induced pain.
Figure 1 Inhibition of BDNF signaling attenuated pain behavior in the rats with bone cancer. (A) Implantation of tumor cells (TCI) into the
tibias significantly increased the protein expression of BDNF in the spinal dorsal horn of the rats (day 5: t = 3.7, P < 0.01; day 15: t = 4.7, P < 0.01;
n = 7 rats in each group); (B) Intrathecal injection of TrkB-Fc (1.5 μg, from day 3 through day 15) attenuated the increase of input (stimuli intensity) –
output (EPSC amplitude) response in the dorsal horn neurons in the modeled rats (F(1,20) = 13.36, P < 0.01, n = 9–12 neurons per group); (C) Intrathecal
injection of TrkB-Fc significantly recovered the ipsilateral paw withdrawal threshold response to mechanical (F(1, 18) = 11.24, P < 0.01) and radiant thermal
stimuli (F(1, 18) = 10.85, P < 0.01) in the rats with bone cancer (n = 8–10 rats per group). Control vs. TCI: *, P < 0.05; **, P < 0.01; TCI vs. TCI + TrkB-Fc:
♦, P < 0.05; ♦♦, P < 0.01.
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antagonist of PAR2, was daily delivered via the intra-
thecal catheter to determine its effect on BDNF function,glutamatergic strength and pain behavior in the rats with
bone cancer. As shown in Figure 2B, blockade of PAR2
signaling by FSLLRY-NH2 significantly reversed the
Figure 2 (See legend on next page.)
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Figure 2 Inhibition of PAR2 signaling attenuated pain behavior in the rats with bone cancer. (A) Implantation of tumor cells in the tibias
significantly increased the expression of PAR2 in the spinal dorsal horn of the rats (day 5: t = 2.84, P < 0.05; day 15: t = 3.18, P < 0.01; n = 7 rats in
each group); (B) Blockade of PAR2 signaling by FSLLRY-NH2 (10 μg, from day 3 through day 15) significantly attenuated the upregulation of spinal
BDNF in the rats with bone cancer pain (t = 4.21, P < 0.01, n = 7 per group), while no change was observed in the control rats (t = 0.42, P > 0.05, n = 6–7
rats per group); (C) Intrathecal injection of FSLLRY-NH2 significantly attenuated the increase of input (stimuli intensity) – output (EPSC amplitude)
response in the dorsal horn neurons in the modeled rats (F(1, 21) = 10.75, P < 0.01, n = 9–12 neurons per group); (D) Intrathecal injection of FSLLRY-NH2
significantly attenuated the increase of GluR1 (t = 2.57, P < 0.05) and NR2B (t = 2.40, P < 0.05) in the dorsal horn in the modeled rats (n = 6–7 rats per
group); (E) Intrathecal injection of FSLLRY-NH2 significantly recovered the ipsilateral paw withdrawal threshold response to mechanical (F(1, 18) = 10.04,
P < 0.01) and radiant thermal stimuli (F(1, 18) = 12.49, P < 0.01) in the rats with bone cancer (n = 8–10 rats per group); (F) Intrathecal injection of scrambled
peptide failed to change the pain behavior in control and modeled rats (P > 0.05, n = 8–10 rats per group). Control vs. TCI: *, P < 0.05; **, P < 0.01; TCI vs.
TCI + FSLLRY-NH2: ♦, P < 0.05; ♦♦, P < 0.01.
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tumor cells, while it did not obviously change the ex-
pression of spinal BDNF in the control rats. This sug-
gested a PAR2-mediated spinal BDNF upregulation in
the setting of bone cancer pain.
Further recording results demonstrated that, as shown in
Figure 2C, intrathecal delivery of FSLLRY-NH2 significantly
attenuated the enhanced glutamatergic input–output re-
sponse in the dorsal horn neurons of the rats with bone
cancer, while it did not remarkably change the basal gluta-
matergic strength in the control rats (Figure 2C). It was also
found that intrathecal delivery of FSLLRY-NH2 attenuated
the increased expression of glutamate receptor subunits
GluR1 and NR2B in the dorsal horn of the rats with bone
cancer (Figure 2D). As well, behavioral studies also demon-
strated that inhibition of PAR2 signaling by FSLLRY-NH2
significantly attenuated the mechanical allodynia and ther-
mal hyperalgesia in these modeled rats (Figure 2E). Notably,
intrathecal injection of scramble peptides in the same dose
failed to affect the mechanical and thermal pain behaviors
in either control or modeled rats (Figure 2F). These results
suggested that upregulation of PAR2 signaling, via modulat-
ing the expression of BDNF, critically participated in the in-
duction of enhanced spinal glutamatergic transmission and
pain behavior in the rats with bone cancer.
NF-κB mediated BDNF upregulation and glutamatergic
sensitization in the rats with bone cancer-induced pain
Activation of PAR2 signaling may induce the degrad-
ation of NF-κB inhibitor protein IkB, and lead to the ac-
tivation and nuclear translocation of transcription factor
NF-κB [18], which is critically involved in the synaptic
plasticity [16] and processing of nociceptive information
[19]. Here, as shown in Figure 3A, although the total ex-
pression level of NF-κB subunit p65 did not have signifi-
cant change, the phosphorylated p65 was significantly
increased in the ipsilateral dorsal horn of the rats im-
planted with tumor cells. Then, pyrrolidine dithiocarba-
mate (PDTC, 1 μg/10 μl from day 3 to day 15), an
inhibitor of NF-κB, was daily delivered via intrathecal
catheter to suppress the PAR2-NF-κB signaling in the
rats with bone cancer pain. As shown in Figure 3B,blockade of NF-κB signaling by PDTC significantly reversed
the upregulation of spinal BDNF in the rats with bone
cancer-induced pain, while it did not obvious change the ex-
pression of spinal BDNF in the control rats. Further electro-
physiological studies revealed that, as shown in Figure 3C,
intrathecal delivery of PDTC significantly attenuated the en-
hanced glutamatergic strength in the dorsal horn of the rats
implanted with tumor cells, while it did not remarkably
change the basal glutamatergic strength in the control rats.
Meanwhile, behavioral studies also demonstrated that inhib-
ition of NF-κB signaling by PDTC significantly attenuated
the mechanical allodynia and thermal hyperalgesia in these
modeled rats (Figure 3D). These results suggested that
activation of NF-κB signaling contributed to the PAR2-
mediated BDNF upregulation, enhanced spinal glutamater-
gic transmission and pain behavior in the rats with bone
cancer.
Discussion
While inflammatory mediators and cytokines from periph-
eral nociceptors and surrounding immune and epithelial
cells may remarkably sensitize the primary afferent fibers
in the conditions of nociceptive and neuropathic pain
[20], sensitization of nocisponsive neurons in spinal dorsal
horn and supraspinal brain regions also significantly con-
tributes to the persistent characteristics [21] and the nega-
tive affective components of sustained pain [22]. Peripheral
inflammation may drive α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid receptor subunit GluR1 membrane
trafficking and induce hyperreactivity in the dorsal horn
neurons [23]. Peripheral nerve injury also significantly en-
hanced the excitatory glutamatergic transmission in the
dorsal horn neurons, which contributing to the mechanical
allodynia in the neuropathic pain [24]. In the rodent model
of bone cancer pain, the primary sensory afferents inner-
vated in the bone marrow, mineralized bone, and the over-
lying periosteum was sensitized by the inflammatory
microenvironment and injury of sensory and sympathetic
fibers induced by proliferating tumor cells [2]. Meanwhile,
emerging evidences recently indicated that sensitization of
dorsal horn nocisponsive neurons existed in the rodents
with bone cancer pain. Increased expression and phos-
Figure 3 (See legend on next page.)
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Figure 3 Inhibition of NF-κB signaling attenuated pain behavior in the rats with bone cancer. (A) Implantation of tumor cells in the tibias
significantly increased the phosphorylation of NF-κB subunit p65 (t = 2.93, P = 0.01), but not the total p65 (t = 0.54, P > 0.05), in the spinal dorsal
horn of the rats (n = 7 rats in each group); (B) Blockade of NF-κB signaling by PDTC (1 μg, from day 3 through day 15) significantly attenuated
the upregulation of spinal BDNF in the rats with bone cancer-induced pain (t = 3.49, P < 0.01), while no change was observed in the control rats
(t = 0.15, P > 0.05; n = 8–9 rats per group); (C) Intrathecal injection of PDTC significantly attenuated the increase of input (stimuli intensity) – output
(EPSC amplitude) response in the dorsal horn neurons in the modeled rats (F(1, 19) = 9.76, P < 0.01; n = 9–12 neurons per group); (D) Intrathecal
injection of PDTC significantly recovered the ipsilateral paw withdrawal threshold response to mechanical (F(1, 17) = 11.63, P < 0.01) and radiant
thermal stimuli (F(1, 17) = 9.81, P < 0.01) in the rats with bone cancer (n = 9–10 rats per group). Control vs. TCI: *, P < 0.05; **, P < 0.01; TCI vs.
TCI + PDTC: ♦, P < 0.05; ♦♦, P < 0.01.
Bao et al. Molecular Pain 2014, 10:28 Page 7 of 10
http://www.molecularpain.com/content/10/1/28phorylation of NR2B, an N-methyl-D-aspartate receptor
(NMDA) subunit, was reported in the dorsal horn of the
bone cancer pain models [25-27]. In the present study, a
remarkably increased input (stimulation intensity) – output
(EPSC amplitude) response was observed in the dorsal
horn neurons, which substantiating the enhanced spinal
glutamatergic strength and central sensitization in the ro-
dent with bone cancer pain.
Overwhelming evidences demonstrated that BDNF ex-
tensively participated in the neuronal development and
the induction and maintenance of synaptic plasticity in
several brain regions [28]. As well, a growing body of evi-
dence also suggested that BDNF was critically involved in
spinal plasticity and central sensitization in varieties types
of pain. Expression of BDNF was increased in the spinal
dorsal horn of the rodent models of inflammatory or
neuropathic pain [10]. Enhanced BDNF-mediated signal-
ing induces the phosphorylation of NMDA receptor sub-
units and sprouting of spinal nocisponsive fibers [29], and
enhances the communication between microglia and neu-
rons in the dorsal horn [30], thus contributing to the in-
duction and maintenance of the sensitization of spinal
neurons in the circumstance of chronic pain. Here, in the
present study, a significantly increased BDNF in dorsal
horn was revealed, and blocking BDNF signaling largely
attenuated the enhanced glutamatergic strength and pain-
ful behavior in the rodent with bone cancer pain. This
suggested a critical involvement of BDNF in the spinal
sensitization and hypersensitivity to painful stimuli in the
bone cancer pain.
Upon activation, PAR2 receptor may trigger several
intracellular signal cascades involving MAPK signaling,
PLC-mediated phospholipid signaling, and β-arrestin sig-
naling [11]. Among these, activation of PLC-mediated
phospholipid signaling may induce the phosphorylation of
IKKα and IKKβ and lead to activation and nuclear trans-
location of NF-κB [11,18]. Activation of NF-κB - mediated
signaling increased the histone acetylation and facilitated
the expression of BDNF in the central neurons [31]. Actu-
ally, it was recently implied that activation of PAR2 signaling
was required for several inflammatory mediators-induced
BDNF release from the microglia [32,33]. Moreover, the
present study demonstrated that inhibition the activity of
either PAR2 or NF-κB largely attenuated the upregulation ofBDNF in the dorsal horn, indicating that the PAR2 - NF-κB
signaling critically participate in the spinal BDNF upregula-
tion in the bone cancer pain.
PAR2 is expressed in the primary sensory neurons and
nocisponsive neurons in the spinal dorsal horn. Increasing
evidences suggested that activation of PAR2 signaling was
extensively involved in the sensitization of peripheral noci-
ceptors and dorsal horn neurons in inflammatory and
neuropathic pain. Activation of PAR2 and downstream en-
zymes PLC, PKCε, and PKA resulted in the sensitization
of peripheral nociceptors by decreasing the threshold of
transient receptor potential (TRP) ion channels in the cir-
cumstances of peripheral inflammation [34,35] or chemo-
therapeutic agent-induced neuropathic pain [36]. Chronic
compression of dorsal root ganglion (DRG) can activate
PAR2 signaling, leading to increased nociceptor hyperex-
citability and thermal hyperalgesia in the rodents [37,38].
It was recently reported that activation of PAR2 signaling
induced the sensitization of DRG neurons, which contrib-
uting to the thermal and mechanical hyperalgesia in the
rodent model of bone cancer pain [12,13]. The present
study further revealed that activation of PAR2 signaling re-
markably contributed to the enhanced glutamatergic
strength in the dorsal horn neurons, which implying its
role in the induction of central sensitization in bone can-
cer pain. The present study also suggested that activation
of NF-κB signaling may underlie PAR2-mediated BDNF
upregulation, central sensitization and behavioral hyper-
sensitivity in the bone cancer pain.
Conclusion
The present study demonstrated that activation of PAR2
triggered NF-κB signaling and significantly upregulated
the BDNF function, which substantially underlaid the
enhancement of glutamatergic transmission in spinal
dorsal horn and thermal and mechanical hypersensitivity
in the rats with bone cancer pain. This indicated that
PAR2 - NF-κB signaling might become a novel target for
the treatment of pain in patients with bone cancer.
Materials and methods
Animal model of bone cancer pain and drug delivery
Adult female Wistar rats (weighing 200–250 g) were pur-
chased from the Institutional Center of Experiment
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(22 ± 1°C and 12:12 h light cycle) with unrestricted free ac-
cess to food and water. All animal experiments were
approved by the Institutional Animal Care and Use
Committee in China Academy of Chinese Medical
Sciences, and were in strict accordance with the rec-
ommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. All
surgery was performed under appropriate anesthesia,
and all efforts were made to minimize suffering in the
animals.
The rat model of bone cancer pain was established by
implantation of Walker 256 rat mammary gland carcin-
oma cells into the right tibias, as previously reported [3].
Briefly, suspensions of tumor cells in PBS was prepared
as previously described [39]. Tumor cell implantation
was achieved by injecting the tumor cells (1 × 105 cells/
μl, 5 μL) into the intramedullary space of the right tibia
to induce bone cancer in rats under the anesthesia with
pentobarbital (45 mg/kg). Boiled cells were injected with
a similar procedure in the control group. The investiga-
tors who performed behavioral tests, immunoblotting,
and electrophysiological recording were blinded to this
procedure.
Intrathecal cannulation was performed as described pre-
viously [40]. Intrathecal catheters (PE-10 polyethylene tub-
ing) were implanted 1 week before any procedures. The
catheters were advanced 8 cm caudally through an incision
in the cisternal membrane and secured to the musculature
at the incision site. Only animals with no evidence of
neurological deficits after catheter insertion were studied.
TrkB-Fc chimera (1.5 μg, R&D systems cat#: 688-TK-100)
[41], FSLLRY-NH2 (10 μg, Tocris cat#: 4751) [42], pyrroli-
dine dithiocarbamate (PDTC, 1 μg, Sigma cat#: P8765)
[43], or vehicle was administered in a volume of 10 μl
followed by a 10-μl flush with normal saline. The drugs
were given daily from day 3 to day 15 after carcinoma cell
inoculation.
Behavioral tests
Mechanical allodynia and thermal hyperalgesia were
assessed in rats to evaluate painful behavior induced by
tumor cell implantation. Mechanical sensitivity was
assessed by using a series of von Frey filaments with
logarithmic incremental stiffness (Stoelting Co., Wood
Dale, IL), and 50% probability paw withdrawal thresh-
olds were calculated with the up-down method as previ-
ously described [44]. In brief, the animals were placed
individually beneath an inverted ventilated cage with a
metal-mesh floor, and allowed to habituation for 30 mi-
nutes before testing. The filaments were applied to the
plantar surface of the hindpaws for approximately 6 sec-
onds in an ascending or descending order after a nega-
tive or positive withdrawal response, respectively. Sixconsecutive responses after the first change in response
were used to calculate the paw withdrawal threshold (in
grams). The maximum pressure was set as 16 g.
Thermal nociceptive thresholds were measured using
radiant heat [45]. Briefly, rats were placed into individual
plastic cubicles mounted on a glass surface maintained
at 30°C and allowed an hour habituation period. A ther-
mal stimulus (a radiant heat source) was then delivered
to the plantar surface of the hindpaws. The time for the
rat to remove the paw from the thermal stimulus was
electronically recorded as the paw withdrawal latency
(PWL). The stimulus shut off automatically when the
hind paw moved or after 16 seconds to prevent tissue
damage. The intensity of the heat stimulus was main-
tained constant throughout all experiments.
Protein extraction and immunoblotting
After behavioral testing, the rats were deeply anesthetized
with pentobarbital sodium (50 mg/kg), and the ipsilateral
L4-L5 segments were quickly removed and homogenized
in the lysis buffer (25 mM Tris–HCl, pH 7.6, 150 mM
NaCl, 0.1% SDS, 1 mM PMSF, 1 mM NaF, 1 mM NaVO3,
1 μg/ml leupeptin, 1 μg/ml pepstatin, and 1 μg/ml aproti-
nin). The lysates were centrifuged at 14,000 rpm for 10
min at 4°C, and the protein concentrations in the super-
natant were measured by using the Bio-Rad protein assay
kit. The samples (containing 20 μg proteins) were sepa-
rated on a 15% (for BDNF) or 7.5% (for other proteins)
SDS-polyacrylamide gel, and blotted to a nitrocellulose
membrane. The blots were incubated overnight at 4°C with
a rabbit polyclonal anti-BDNF primary antibody (1:250;
Santa Cruz Biotechnology cat#: sc-546), monoclonal anti-
PAR2 antibody (1:1000; Millipore cat#: MABF243), poly-
clonal anti-NF-κB p65 (1:1000, Abcam cat#: ab7970),
anti-phosphorylated NF-κB p65 (1:1000, Abcam cat#:
ab106129), or monoclonal anti-β-actin antibody (1:2000;
Santa Cruz Biotechnology, cat#: sc-81178). The mem-
branes were washed extensively with Tris-buffered saline
and incubated with horseradish peroxidase-conjugated
anti-mouse and anti-rabbit IgG antibody (1:10,000; Jackson
ImmunoResearch Laboratories Inc., West Grove, PA). The
immunoreactivity was detected using enhanced che-
miluminescence (ECL Advance Kit; Amersham Biosciences).
The intensity of the bands was captured digitally and an-
alyzed quantitatively with Image J software. The immuno-
reactivities of target proteins were normalized to that of
β-actin.
Spinal cord slice preparation and electrophysiological
recording
The rats were deeply anesthetized with inhalation of halo-
thane, and the lumbar segment of the spinal cord was re-
moved through laminectomy. The spinal tissue was
immediately placed in ice-cold artificial cerebrospinal fluid
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CaCl2 2.0, NaH2PO4 1.2, glucose 12, and NaHCO3 25.
Transverse spinal cord slices (400 μm) were cut with a
vibratome (Technical Products International, St. Louis,
MO), and incubated in Krebs’ solution (containing: 117
mM NaCl, 3.6 mM KCl, 1.2 mM MgCl2, 2.5 mM CaCl2,
1.2 mM NaH2PO4, 11 mM glucose, and 25 mM NaHCO3,
bubbled with 95% O2 and 5% CO2) at 35°C for at least 1 h
before the recording was performed.
Whole-cell recording on the spinal cord slices (L4-L5)
was performed as described previously [40]. The neurons
in lamina II of the ipsilateral dorsal horn were visualized
using an upright microscope with infrared illumination
(BX50WI; Olympus, Tokyo). Whole-cell voltage-clamp re-
cordings were performed using an Axopatch 200B ampli-
fier (Molecular Devices) with 3–5 MΩ glass electrodes
containing the following internal solution (in mM): K-
gluconate, 126; NaCl, 5; MgCl2 1.2; EGTA, 0.5; Mg-ATP,
2; Na3GTP, 0.1; HEPES, 10; guanosine 5-O-(2-thiodipho-
sphate) 1; lidocaine N-ethyl bromide (QX314), 10; pH 7.3;
290 – 300 mOsmol. A seal resistance of ≥ 2 GΩ and an ac-
cess resistance of 15 – 20 MΩ were considered acceptable.
The series resistance was optimally compensated by ≥70%
and constantly monitored throughout the experiments. The
membrane potential was held at −60 mV throughout the
experiment. Excitatory postsynaptic currents (EPSCs) in ip-
silateral lamina II neurons were evoked by electrical stimu-
lation (0.25 ms, 0.05 – 0.3 mA) of the dorsal root in the
presence of strychnine (2 μM) and bicuculline (10 μM).
The evoked EPSCs were filtered at 2 kHz, digitized at 10
kHz, and acquired and analyzed using pCLAMP 9.2 soft-
ware (Molecular Devices).
Statistical analysis
All data were presented as means ± SEM. For analysis of
immunoblotting data, differences between groups were
compared by Student’s t-test or ANOVA followed by
Fisher’s PLSD post hoc analysis. The electrophysiological
and behavioral data were compared with two-way
ANOVA with repeated measurements. The criterion for
statistical significance was P < 0.05. Statistical tests were
performed with SPSS 13.0 (SPSS, USA).
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